coin-img-ETHETH+0.50%coin-img-BTCBTC+1.16%coin-img-SOLSOL+8.79%coin-img-CTMCTM+35.31%coin-img-XRPXRP+1.00%coin-img-USDCUSDC-0.02%coin-img-TRXTRX-0.96%coin-img-HYPEHYPE+6.98%coin-img-ETHETH+0.50%coin-img-BTCBTC+1.16%coin-img-SOLSOL+8.79%coin-img-CTMCTM+35.31%coin-img-XRPXRP+1.00%coin-img-USDCUSDC-0.02%coin-img-TRXTRX-0.96%coin-img-HYPEHYPE+6.98%coin-img-ETHETH+0.50%coin-img-BTCBTC+1.16%coin-img-SOLSOL+8.79%coin-img-CTMCTM+35.31%coin-img-XRPXRP+1.00%coin-img-USDCUSDC-0.02%coin-img-TRXTRX-0.96%coin-img-HYPEHYPE+6.98%coin-img-ETHETH+0.50%coin-img-BTCBTC+1.16%coin-img-SOLSOL+8.79%coin-img-CTMCTM+35.31%coin-img-XRPXRP+1.00%coin-img-USDCUSDC-0.02%coin-img-TRXTRX-0.96%coin-img-HYPEHYPE+6.98%

Kobo Biotech FY25 net loss widens to ₹5.23 crore as operations remain suspended

Kobo Biotech reported a wider FY25 net loss of ₹5.23 crore and recorded no revenue from operations. The company entered the Corporate Insolvency Resolution Process (CIRP) on August 13, 2024, after a prolonged production shutdown and financial stress. On May 11, 2026, the NCLT Hyderabad Bench approved Beaufond Industries’ resolution plan. Under the plan, existing shareholders will be heavily diluted to 2%, with financial and governance control fully transferred.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks